A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.

Trial Details

NCT ID

NCT06522737

Phase

PHASE3

Sponsor

SecuraBio

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Duvelisib
Gemcitabine
Bendamustine

Locations (sample)

Ghent, Belgium|51.05,3.71667
Leuven, Belgium|50.87959,4.70093
Prague, Czechia|50.08804,14.42076
Aarhus, Denmark|56.15674,10.21076
Copenhagen, Denmark|55.67594,12.56553

Key Eligibility Criteria

Pathologically confirmed nodal T cell lymphoma with TFH phenotype according to the criteria of the World Health Organization classification (Swerdl…
Relapsed or refractory to at least 1 prior systemic, cytotoxic therapy for T cell lymphoma.
Measurable disease as defined by Lugano 2014 criteria (Cheson 2014) for T cell lymphoma.
Key Exclusion Criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →